Related Experiment Videos
[Clinical analysis of antibiotic treatment for febrile neutropenia]
Hisako Shibata1, Takahisa Yamane, Erina Sakamoto
1Clinical Hematology and Clinical Diagnostics, Osaka City University, Graduate School of Medicine.
Abstract:
Patients with hematological malignancies and aplastic anemia become complicated by critical infections, which are one of the common causes of death in many cases. This is a retrospective investigation of the factors that affect the efficacy of antibiotic treatment of febrile neutropenia (FN). The subjects consisted of 98 cases that developed FN during their hospitalization in this department and received antibiotics as a first-line treatment. Parameters evaluated were age, gender, with or without administration of granulocyte-colony stimulating factor (G-CSF), with or without hematopoietic transplantation, the number of antibiotics, the type of antibiotics, the highest level of C-reactive protein (CRP), with or without antifungal prophylaxis, the duration of neutropenia, and the number of neutrophils before and after the administration of antibiotics. Logistic analysis was used for statistical evaluation. With univariate analysis, significant clinical efficacy was observed with the use of carbapenems (p = 0.0009, Odds; 4.58) when the number of neutrophils was not less than 500/microL (P < 0.0001, Odds: 14.1) after administration of antibiotics. Furthermore, even when multivariate analysis was performed, significant clinical efficacy was observed independently in the use of carbapenems (P = 0.02, Odds: 3.73) and when the number of neutrophils was not less than 500/microL (P < 0.0001, Odds: 10.4) after administration of antibiotics. In this investigation, as a first-line treatment of FN, carbapenem antibiotic is recommended as a primary choice, when the number of neutrophils was expected to decrease after administration.
Insights
For febrile neutropenia (FN) in cancer patients, carbapenem antibiotics are recommended as a first-line treatment. This is especially effective when neutrophil counts are expected to remain low after antibiotic administration.
Area of Science:
- Hematology
- Infectious Diseases
- Pharmacology
Context:
- Febrile neutropenia (FN) is a critical complication in patients with hematological malignancies and aplastic anemia, often leading to mortality.
- Effective antibiotic treatment is crucial for managing FN and improving patient outcomes.
Purpose:
- To retrospectively investigate factors influencing the efficacy of first-line antibiotic treatment for febrile neutropenia (FN).
- To identify optimal antibiotic strategies for patients with hematological malignancies and aplastic anemia experiencing FN.
Summary:
- This retrospective study analyzed 98 FN cases, evaluating parameters like age, G-CSF use, transplantation status, antibiotic type, CRP levels, and neutrophil counts.
- Univariate and multivariate analyses indicated that carbapenem antibiotics significantly improved clinical efficacy (Odds: 3.73-4.58) when neutrophil counts were ≥500/microL post-treatment (Odds: 10.4-14.1).
Impact:
- Recommends carbapenem antibiotics as a primary choice for first-line FN treatment, particularly when neutrophil recovery is anticipated to be poor.
- Highlights the importance of monitoring neutrophil counts in conjunction with antibiotic selection for managing FN in vulnerable patient populations.
